Furthermore, a multi-center cohort study of 85 HCC patients treated with atezolizumab and bevacizumab found that 26 patients with TERT gene mutations had significantly shorter OS compared to those without TERT mutations. The gene discussed is TERT; the disease is hepatocellular carcinoma.